Waypoint Bio, a biotechnology company pioneering novel cell therapies for solid tumors using in vivo spatial pooled screening technology, announced $14.5 million in seed funding led by Hummingbird Ventures with participation from other institutional investors, including Recode Ventures and pre-seed lead Fifty Years.